Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Lucid Diagnostics
LUCD
Lucid Diagnostics
Medicare Coverage Delays Will Exacerbate Cash Burn Yet Yield Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
17 Aug 25
Updated
17 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$2.00
45.0% undervalued
intrinsic discount
17 Aug
US$1.10
Loading
1Y
34.3%
7D
7.8%
Author's Valuation
US$2.0
45.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$2.0
45.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-89m
34m
2018
2020
2022
2024
2025
2026
2028
Revenue US$33.7m
Earnings US$4.2m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
49.17%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.02%
Calculation
US$4.19m
Earnings '28
x
134.98x
PE Ratio '28
=
US$565.19m
Market Cap '28
US$565.19m
Market Cap '28
/
223.86m
No. shares '28
=
US$2.52
Share Price '28
US$2.52
Share Price '28
Discounted to 2025 @ 8.07% p.a.
=
US$2.00
Fair Value '25
